Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Vistagen Therapeutics (VTGN) Accumulated Depreciation & Amortization (2017 - 2025)

Vistagen Therapeutics' Accumulated Depreciation & Amortization history spans 9 years, with the latest figure at $150000.0 for Q1 2025.

  • For Q1 2025, Accumulated Depreciation & Amortization rose 18.11% year-over-year to $150000.0; the TTM value through Mar 2025 reached $150000.0, up 18.11%, while the annual FY2025 figure was $150000.0, 18.11% up from the prior year.
  • Accumulated Depreciation & Amortization for Q1 2025 was $150000.0 at Vistagen Therapeutics, up from $127000.0 in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $150000.0 in Q1 2025 and bottomed at $31500.0 in Q2 2023.
  • The 4-year median for Accumulated Depreciation & Amortization is $114900.0 (2021), against an average of $87457.1.
  • The largest YoY upside for Accumulated Depreciation & Amortization was 335.23% in 2021 against a maximum downside of 96.75% in 2021.
  • A 4-year view of Accumulated Depreciation & Amortization shows it stood at $114900.0 in 2021, then tumbled by 72.58% to $31500.0 in 2023, then soared by 303.17% to $127000.0 in 2024, then grew by 18.11% to $150000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Accumulated Depreciation & Amortization are $150000.0 (Q1 2025), $127000.0 (Q1 2024), and $31500.0 (Q2 2023).